Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults
Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies. Participants must have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut.
Enrollment: This trial is active and currently enrolling.
How to Participate: For more information, call 214-456-1438 or email email@example.com
Who Can Participate: Anyone between the ages of 2-55 years who has a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut or walnut.
Age Range: 2-55 years
Estimated Time Commitment (# of visits, etc.): This is a multi-stage study, with an individual study participation of up to 4 years and 8 months, but not past December 2023.
Study Location: Children’s Medical Center, Dallas
Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
The primary objective is to compare the ability to consume foods without dose-limiting symptoms during a double-blind placebo-controlled food challenge (DBPCFC) after treatment with either omalizumab or placebo for omalizumab.